-
Electronic (PDF)
-
Site License
-
Enterprisewide
Trubion Pharmaceuticals, Inc. (TRBN) - Financial and Strategic Analysis Review
GlobalData, September 2010, Pages: 32
Trubion Pharmaceuticals Inc. (Trubion), formerly Genecraft, LLC is a bio-pharmaceutical company engaged in the development of protein therapeutic product candidates for the treatment of autoimmune diseases and cancer. It works with a mission to develop a variety of first-in-class and best-in-class products, customized for optimal safety, efficacy, and convenience in order to provide improved patient benefits. The company's product candidates are small modular immuno pharmaceuticals (SMIP) that are designed using its custom drug assembly technology. TRU-015 is the lead product of Trubion, which is in phase IIb clinical trial for the treatment of rheumatoid arthritis.
Trubion Pharmaceuticals, Inc. Key Recent Developments
Aug 16, 2010 Trubion Reports Net Loss Of $5.7 Million For Q2 2010
Jun 03, 2010 Trubion Wins Genentech And Biogen Idec Patent Appeal
May 06, 2010 Trubion Reports Net Loss Of $6.1 Million For Q1 2010
Jan 11, 2010 Trubion, Pfizer Initiate Phase 2 Rheumatoid Arthritis Study
Dec 08, 2009 Trubion, Facet Biotech Present Positive TRU-016 Data
This comprehensive SWOT profile of Trubion Pharmaceuticals, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including,
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities - A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note-: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include,
You get detailed information about the company and its operations to identify potential customers and suppliers.
-The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key
competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered
in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and
efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
List of Tables
List of Figures
Section 1 - About the Company
Trubion Pharmaceuticals, Inc. - Key Facts
Trubion Pharmaceuticals, Inc. - Key Employees
Trubion Pharmaceuticals, Inc. - Key Employee Biographies
Trubion Pharmaceuticals, Inc. - Major Products and Services
Trubion Pharmaceuticals, Inc. - History
Trubion Pharmaceuticals, Inc. - Company Statement
Trubion Pharmaceuticals, Inc. - Locations And Subsidiaries
Head Office
Section 2 - Company Analysis
Trubion Pharmaceuticals, Inc. - Business Description
Trubion Pharmaceuticals, Inc. - SWOT Analysis
SWOT Analysis - Overview
Trubion Pharmaceuticals, Inc. - Strengths
Strength - Proprietary Product Technologies
Strength - Strong Product Portfolio
Strength - Expanding Market Share
Strength - Strong Liquidity Position
Trubion Pharmaceuticals, Inc. - Weaknesses
Weakness - Negative Margins
Weakness - Low Return on Equity
Trubion Pharmaceuticals, Inc. - Opportunities
Opportunity - Strategic Collaborations
Opportunity - Emerging Markets
Opportunity - Growing Oncology Market
Trubion Pharmaceuticals, Inc. - Threats
Threat - Tightening of FDA’s Regulatory Oversight
Threat - Intense Competition
Threat - Uncertain R&D Outcomes
Trubion Pharmaceuticals, Inc. - Key Competitors
Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 - Company’s Recent Developments
Aug 16, 2010: Trubion Reports Net Loss Of $5.7 Million For Q2 2010
Jun 03, 2010: Trubion Wins Genentech And Biogen Idec Patent Appeal
May 06, 2010: Trubion Reports Net Loss Of $6.1 Million For Q1 2010
Jan 11, 2010: Trubion, Pfizer Initiate Phase 2 Rheumatoid Arthritis Study
Dec 08, 2009: Trubion, Facet Biotech Present Positive TRU-016 Data
Nov 16, 2009: Trubion Names Steven Gillis As Acting President
Aug 28, 2009: Facet Biotech Signs Worldwide Collaboration Agreement With Trubion
Aug 06, 2009: Trubion Pharmaceuticals Reports $4.1m Q2 Revenue
Jun 22, 2009: Trubion Extends Research Period With Wyeth
Feb 25, 2009: Trubion Reduces Work-Force by 25%
Section 5 - Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer
Trubion Pharmaceuticals Inc. (Trubion), formerly Genecraft, LLC is a bio-pharmaceutical company engaged in the development of protein therapeutic product candidates for the treatment of autoimmune diseases and cancer. It works with a mission to develop a variety of first-in-class and best-in-class products, customized for optimal safety, efficacy, and convenience in order to provide improved patient benefits. The company's product candidates are small modular immuno pharmaceuticals (SMIP) that are designed using its custom drug assembly technology. TRU-015 is the lead product of Trubion, which is in phase IIb clinical trial for the treatment of rheumatoid arthritis.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
